Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of tumor-agnostic therapies. Focusing on KEYTRUDA, VITRAKVI, and ROZLYTREK, the panel discuss how they are managing these therapies as more of them launch in the future.

Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of gene therapies, both now and in the future. Focusing on the launch of ZOLGENSMA - the panel discuss the potential considerations surrounding cost, management, push-back, and the lack of long-term data available.

Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications. Focusing on TAZVERIK, the panel discuss management expectations, and also disclose whether the expectations of likelihood for approval is ever conferred with them directly